KURA
Kura Oncology, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 5 ▲ Kura Oncology reported Q4 and full-year 2025 financial results, high…
- Apr 17 ▲ Kura Oncology announced preliminary clinical data from a subset of p…
- May 18 to May 21 ▼ 3 days of insider sells: $151.6K by 3 insiders, avg $10.45
- Jun 18 ▼ 1 insider sell $834.3K at $9.82
- Aug 17 to Aug 24 ▲ 2 days of insider buys: $2.4M by 1 insider, avg $11.76
- Aug 19 to Aug 21 ▼ 2 days of insider sells: $449.3K by 2 insiders, avg $12.54
- Sep 9 ▲ Kura Oncology formed a wholly owned subsidiary, Caspian Therapeutics…
- Sep 24 to Sep 29 ▼ 3 days of insider sells: $1.3M by 6 insiders, avg $10.66
- Sep 29 ▲ Kura Oncology and Caspian Therapeutics announced preclinical data fo…
- Sep 29 FDA: Caspian Therapeutics Unveils KO-7246 at EASD as a Potentia…
- Oct 1 JP Morgan initiates
- Nov 4 Contract: Kura Oncology and Kyowa Kirin to Present First Ziftomenib-…
- Nov 13 New insider trade: subscribers see the details Unlock
- Nov 16 New insider trade: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersMIXED
1 insider bought $2.4M. 6 insiders sold $2.7M. Excludes 2 subscriber-only trades.
- InstitutionsBULLISH
Q3 2026: 25 added (0 new), 14 trimmed or exited.
- AnalystsBULLISH
20 of 22 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.892 → −$0.811 over 90 days.
- Short sellersSTEADY
Short interest −11.7% to 12.64M shares. 7.9 days to cover, ≈14.2% of shares.
- TrendDOWNTREND
29% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | $29.5M |
| Qube Research & Technologies Ltd | ADD | $19.8M |
| JUPITER ASSET MANAGEMENT LTD | DOUBLED | $15.7M |
| HRT FINANCIAL LP | DOUBLED | $12.8M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | $7.3M |
| FMR LLC | ADD | $6.9M |
| Jump Financial, LLC | TRIM | $4.0M |
| FRANKLIN TEMPLETON INC | DOUBLED | $2.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
22 analystsPrice is below the lowest target. Median implies +295%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 1, 2026 | JP Morgan INITIATE | Overweight |
| Aug 24, 2026 | Citizens REITERATE | Market Outperform |
| Aug 13, 2026 | Wedbush MAINTAIN | Outperform |
| Jul 28, 2026 | Wedbush REITERATE | Outperform |
| Jun 15, 2026 | Citizens REITERATE | Market Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Nov 16, 2026 | BUY | |
| 🔒 Fresh data, subscribers only Nov 13, 2026 | BUY | |
FORD KATHLEEN Chief Operating Officer Sep 29, 2026 | SELL | $39.4K |
Leoni Mollie Chief Medical Officer Sep 29, 2026 | SELL | $309.6K |
Powl Brian T. Chief Commercial Officer Sep 29, 2026 | SELL | $165.9K |
FORD KATHLEEN Chief Operating Officer Sep 28, 2026 | SELL | $72.5K |
Leoni Mollie Chief Medical Officer Sep 28, 2026 | SELL | $130.7K |
DOYLE THOMAS JAMES SVP, Finance & Accounting Sep 28, 2026 | SELL | $48.4K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.81 | -$0.99–-$0.69 | -0.6% | $31.7M |
| Next Q | -$0.69 | -$0.80–-$0.60 | -1.5% | $39.4M |
| Current FY | -$3.21 | -$3.45–-$3.07 | -1.2% | $94.0M |
| Next FY | -$2.39 | -$3.31–-$1.75 | -1.7% | $200.4M |
Short side
FINRA· Oct 30, 2026SecBot reports
20 filings · 9 press releases · 7 bullish · 1 bearish · 1 mixed · 11 neutral- BULLISH INSIDER-BUYNov 16, 2026
CEO Troy Wilson purchased $1.5M of KURA stock in two open-market trades on Nov 13 and Nov 16, 2026, following the company's Q3 earnings report showing 53% sequential KOMZIFTI revenue growth to $13.9M. The insider buying represents 0.22% of market cap and signals confidence in the commercial…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 16, 2026
Five Kura Oncology officers filed Form 144 notices on November 16, 2026, signaling intent to sell shares acquired from vesting RSUs and PSUs. The filings cover the Chief Commercial Officer, SVP Finance & Accounting, Chief Legal Officer, Chief Operating Officer, and Chief Medical Officer.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Biotechnology Value Fund L.P. and related entities filed an amended Schedule 13G disclosing aggregate beneficial ownership of 6,690,108 shares (7.5%) of Kura Oncology as of September 30, 2026, down from a prior stake. The filing confirms a passive investment intent under Rule 13d-1(c).
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL S-3ASRNov 10, 2026
Kura Oncology filed an automatic shelf registration statement (S-3ASR) as a well-known seasoned…
The ATM facility provides Kura with flexible, opportunistic capital access given its strong cash position and recent commercial momentum. Monitor actual ATM usage in future filings; the company may…
All KURA filing & press-release reports (29)
- INSIDER-BUY reportNov 16, 2026
- 144 reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- S-3ASR reportNov 10, 2026
- PRESS-RELEASE reportNov 10, 2026
- PRESS-RELEASE reportNov 4, 2026
- CLUSTER reportSep 29, 2026
- PRESS-RELEASE reportSep 29, 2026
- 8-K reportSep 8, 2026
- 8-K reportSep 9, 2026
- CLUSTER reportAug 24, 2026
- CLUSTER reportAug 21, 2026
- INSIDER-BUY reportAug 17, 2026
- PRESS-RELEASE reportAug 12, 2026
- PRESS-RELEASE reportAug 5, 2026
- 8-K reportJul 29, 2026
- PRESS-RELEASE reportJul 14, 2026
- PRESS-RELEASE reportJun 3, 2026
- PRESS-RELEASE reportJun 2, 2026
- DEFA14A reportMay 26, 2026
- PRESS-RELEASE reportMay 26, 2026
- CLUSTER reportMay 22, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- PRESS-RELEASE reportApr 17, 2026
- DEFA14A reportApr 10, 2026
- 8-K reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026
- INST-CLUSTER reportFeb 28, 2026